Ucb S.a. · EURONEXT:UCB
Ucb — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
13 slides from Ucb's conference presentation, Jan 15, 2025
Slide 1: UCB's Decade+ of Growth
UCB’s Decade+ of Growth Proprietary and Confidential Property of UCB Elevating lives of people through our medicines Jean-Christophe Tellier, CEO 43rd Annual J.P. Morgan Healthcare Conference January 15th, 2025 UCB – 43rd Annual J.P. Morgan Healthcare Conference, 15th January 2025 1
Slide 2: Disclaimer & Safe harbor
Disclaimer & Safe harbor This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-loo
Slide 3: Introduction to UCB
Introduction to UCB Creating VALUE FOR PATIENTS now and into the future Proprietary and Confidential Property of UCB Longstanding legacy and ~100 yrs 3.2 M >9,000 25%-30% R&D Ratio Above Excellence in Patient Lives Employees* leadership Biopharmaceuticals Impacted* Industry Average in the Past Decad
Slide 4: Our Strategy
Proprietary and Confidential Property of UCB Our Strategy UCB – 43rd Annual J.P. Morgan Healthcare Conference, 15th January 2025 4
Slide 5: Our Legacy Defines Us
Our Legacy Defines Us Initiated in 2015, PATIENT VALUE STRATEGY (PVS) is our COMPANY STRATEGY 25 approvals & launches in key regions (U.S., EU and Japan) in the last 24 months Proprietary and Confidential Property of UCB and many more around the globe 2 0 2 2 - 2 0 2 3 - 2 0 2 4 - 2 0 2 5 Industry-l
Slide 6: Our Present Positions Us
Our Present Positions Us We have in our hands a STRONG COMMERCIAL PORTFOLIO and CUTTING-EDGE PIPELINE Decade+ of Growth Long-Term Growth (Beyond Decade+) Unique & differentiated portfolio serving 9 patient populations Pipeline progress securing the growth* Proprietary and Confidential Property of UC
Slide 7: Our Execution
Proprietary and Confidential Property of UCB Our Execution UCB – 43rd Annual J.P. Morgan Healthcare Conference, 15th January 2025 7
Slide 8: Years of Strong Growth and More to Come
10 Years of Strong Growth and More to Come Continued INVESTMENT IN INNOVATION to deliver growth and SHAREHOLDER VALUE Annual Revenue Adjusted EBITDA Market Cap € 37bn Proprietary and Confidential Property of UCB € 6bn 3x +50% € 3.9bn € 1.4bn € 12bn +75% € 0.8bn 2015 2024 2015 2024 2015 2024 Actual P
Slide 9: Key Growth Driver: BIMZELX
Key Growth Driver: BIMZELX® Recognition of INNOVATION LEADING TO PATIENT VALUE l Significantly improved access in the U.S.* BIMZELX® | Uptake vs. other interleukin antibodies Very favorable commercial coverage among all Performance with 2024 Coverage** IL-17s for Psoriasis (JAN25), with zero exclusi
Slide 10: Further Growth Drivers: RYSTIGGO, ZILBRYSQ, EVENITY, FINTEPLA
Further Growth Drivers: RYSTIGGO®, ZILBRYSQ ®, EVENITY®, FINTEPLA® Increasing the BREADTH AND DEPTH of our portfolio RYSTIGGO® & ZILBRYSQ® • First and only company with differentiated gMG portfolio • RYSTIGGO® - First agent for anti-AChR+ and anti-MuSK+ gMG Proprietary and Confidential Property of U
Slide 11: Our Mission Drives Us Forward in Our Decade+ of Growth
Our Mission Drives Us Forward in Our Decade+ of Growth Our strategy is to ELEVATE THE LIVES OF PEOPLE through our medicines Go beyond symptom management, targeting disease modification and potential cures Proprietary and Confidential Property of UCB Deliver measurable benefits for patients, families
Slide 12: Breakthrough innovation to elevate lives of people through our medicines
Breakthrough innovation to elevate lives of people through our medicines Proprietary and Confidential Property of UCB Differentiated solutions and cutting-edge pipeline to unlock growth for a decade+ and beyond Commitment to delivering value to patients, Breakthrough Innovation & shareholders, emplo
Slide 13: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB
UCB — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix